|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
US5525491A
(en)
|
1991-02-27 |
1996-06-11 |
Creative Biomolecules, Inc. |
Serine-rich peptide linkers
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
EP1002861A1
(en)
|
1998-10-26 |
2000-05-24 |
Unilever Plc |
Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
US7563869B2
(en)
*
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
HUE038955T2
(hu)
|
2003-11-05 |
2018-12-28 |
Roche Glycart Ag |
Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
|
|
PT1718677E
(pt)
|
2003-12-19 |
2012-07-18 |
Genentech Inc |
Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
|
|
CN100376599C
(zh)
|
2004-04-01 |
2008-03-26 |
北京安波特基因工程技术有限公司 |
基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
|
|
WO2005100402A1
(en)
|
2004-04-13 |
2005-10-27 |
F.Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
JP5238936B2
(ja)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール，インク． |
Ｇｉｔｒ結合分子およびその使用
|
|
EP1877090B1
(en)
|
2005-05-06 |
2014-01-15 |
Providence Health System |
Trimeric ox40-immunoglobulin fusion protein and methods of use
|
|
SG170091A1
(en)
|
2006-03-10 |
2011-04-29 |
Wyeth Corp |
Anti-5t4 antibodies and uses thereof
|
|
CN101952312A
(zh)
|
2007-07-31 |
2011-01-19 |
米迪缪尼有限公司 |
多特异性表位结合蛋白及其应用
|
|
EP2190861A4
(en)
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
US8557965B2
(en)
|
2008-04-07 |
2013-10-15 |
Ablynx N.V. |
Single variable domains against notch pathway members
|
|
US20110097339A1
(en)
|
2008-07-18 |
2011-04-28 |
Domantis Limited |
Compositions monovalent for CD28 binding and methods of use
|
|
MX2011000501A
(es)
|
2008-07-18 |
2011-05-23 |
Squibb Bristol Myers Co |
Composiciones monovalentes para union a cd28 y metodos de uso.
|
|
MX2011003502A
(es)
|
2008-10-01 |
2011-09-01 |
Micromet Ag |
Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
US8399219B2
(en)
|
2009-02-23 |
2013-03-19 |
Cytomx Therapeutics, Inc. |
Protease activatable interferon alpha proprotein
|
|
CN102361884A
(zh)
|
2009-04-07 |
2012-02-22 |
罗氏格黎卡特股份公司 |
双特异性抗-ErbB-2/抗-c-Met抗体
|
|
TWI507525B
(zh)
|
2009-06-26 |
2015-11-11 |
Regeneron Pharma |
具天然免疫球蛋白形式之易分離的雙專一性抗體
|
|
IN2015DN02826A
(cg-RX-API-DMAC10.html)
|
2009-09-03 |
2015-09-11 |
Merck Sharp & Dohme |
|
|
JP6002659B2
(ja)
|
2010-04-13 |
2016-10-05 |
セルデックス・セラピューティクス・インコーポレイテッド |
ヒトｃｄ２７に結合する抗体およびその使用
|
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
LT2609118T
(lt)
|
2010-08-23 |
2017-04-25 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antikūnai ir jų panaudojimo būdai
|
|
BR112013002167A2
(pt)
|
2010-08-24 |
2016-05-31 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
|
|
NZ729044A
(en)
|
2010-09-09 |
2020-07-31 |
Pfizer |
4-1bb binding molecules
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
WO2012162067A2
(en)
|
2011-05-21 |
2012-11-29 |
Macrogenics, Inc. |
Cd3-binding molecules capable of binding to human and non-human cd3
|
|
WO2013022091A1
(ja)
*
|
2011-08-11 |
2013-02-14 |
小野薬品工業株式会社 |
Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
|
|
MX2014003313A
(es)
|
2011-09-23 |
2014-07-09 |
Amgen Res Munich Gmbh |
Moleculas de union biespecificas para 5t4 y cd3.
|
|
US9346884B2
(en)
|
2011-09-30 |
2016-05-24 |
Ablynx N.V. |
Biological materials related to c-Met
|
|
KR101814370B1
(ko)
*
|
2011-12-27 |
2018-01-12 |
재단법인 생물기술개발중심 |
경쇄-가교된 이중특이성 항체
|
|
US20140140989A1
(en)
|
2012-02-06 |
2014-05-22 |
Inhibrx Llc |
Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
BR112015000798A2
(pt)
|
2012-07-13 |
2017-06-27 |
Zymeworks Inc |
heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
|
|
CN104640561A
(zh)
|
2012-07-23 |
2015-05-20 |
酵活有限公司 |
包含轻链和重链的选择性配对的免疫球蛋白构建体
|
|
US20150239991A1
(en)
|
2012-09-25 |
2015-08-27 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
|
MX2015003616A
(es)
|
2012-10-08 |
2015-06-05 |
Roche Glycart Ag |
Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
|
|
CA2889951C
(en)
|
2012-11-02 |
2023-04-18 |
Zymeworks Inc. |
Crystal structures of heterodimeric fc domains
|
|
EA032681B1
(ru)
|
2012-11-27 |
2019-07-31 |
Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн |
ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
|
|
US9703815B2
(en)
|
2012-12-17 |
2017-07-11 |
Salesforce.Com, Inc. |
Third party files in an on-demand database service
|
|
KR20150095684A
(ko)
|
2012-12-18 |
2015-08-21 |
노파르티스 아게 |
히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP3587448B1
(en)
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric proteins
|
|
JP6693872B2
(ja)
|
2013-07-25 |
2020-05-13 |
シトムクス セラピューティクス，インコーポレイティド |
多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
KR20250051130A
(ko)
|
2013-09-25 |
2025-04-16 |
싸이톰스 테라퓨틱스, 인크. |
매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
|
|
EP3628328B1
(en)
|
2014-01-31 |
2022-09-14 |
Cytomx Therapeutics Inc. |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
|
KR20160146747A
(ko)
|
2014-03-31 |
2016-12-21 |
제넨테크, 인크. |
항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
|
|
JP2017514522A
(ja)
|
2014-05-02 |
2017-06-08 |
エモリー ユニバーシティー |
ヒト化可変性リンパ球受容体（ｖｌｒ）および組成物ならびにそれに関連する使用
|
|
GB201411420D0
(en)
|
2014-06-26 |
2014-08-13 |
Ucb Biopharma Sprl |
Antibody constructs
|
|
AU2015279321B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma, S.A. |
Multispecific antigen binding proteins
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
PL3177643T3
(pl)
|
2014-08-04 |
2019-09-30 |
F.Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
|
|
EP2982693A1
(en)
*
|
2014-08-07 |
2016-02-10 |
Affimed Therapeutics AG |
CD3 binding domain
|
|
KR102485788B1
(ko)
|
2014-08-27 |
2023-01-09 |
메모리얼 슬로안 케터링 캔서 센터 |
항체, 조성물 및 용도
|
|
WO2016034666A1
(en)
|
2014-09-04 |
2016-03-10 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
|
EP3197916A2
(en)
|
2014-09-25 |
2017-08-02 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
|
JP2017536341A
(ja)
|
2014-10-09 |
2017-12-07 |
エンクマフ アーゲー |
卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体
|
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
|
|
WO2016087416A1
(en)
*
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
ES2935274T3
(es)
|
2014-12-05 |
2023-03-03 |
Merck Patent Gmbh |
Anticuerpo con intercambio de dominios
|
|
MX384198B
(es)
|
2014-12-19 |
2025-03-14 |
Chiome Bioscience Inc |
Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
CA3081058C
(en)
*
|
2015-01-16 |
2024-02-20 |
Academia Sinica |
Linker units and their uses in configuring pharmaceutical molecules
|
|
IL300408B2
(en)
|
2015-01-20 |
2025-11-01 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
|
|
TW201632559A
(zh)
|
2015-02-22 |
2016-09-16 |
索倫多醫療公司 |
結合ｃｄ１３７之抗體治療劑
|
|
MA41613A
(fr)
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
|
|
PH12017501583B1
(en)
|
2015-05-04 |
2023-01-20 |
Pieris Pharmaceuticals Gmbh |
Novel proteins specific for cd137
|
|
EP3292152A1
(en)
|
2015-05-07 |
2018-03-14 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
|
ES2984656T3
(es)
|
2015-05-13 |
2024-10-30 |
Ablynx Nv |
Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3
|
|
WO2016192613A1
(zh)
|
2015-06-01 |
2016-12-08 |
中山大学 |
具有融合至常规Fab片段的单域抗原结合片段的二价抗体
|
|
EP3325512B1
(en)
|
2015-07-23 |
2023-09-06 |
Inhibrx, Inc. |
Multivalent and multispecific gitr-binding fusion proteins
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
CN105384825B
(zh)
*
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
JP2018523686A
(ja)
|
2015-08-17 |
2018-08-23 |
マクロジェニクス，インコーポレーテッド |
Ｂ７‐ｈ３及びｃｄ３に結合できる二重特異性１価ダイアボディ並びにその使用
|
|
MY206406A
(en)
|
2015-10-02 |
2024-12-16 |
Hoffmann La Roche |
Bispecific antibodies specific for a costimulatory tnf receptor
|
|
PE20181349A1
(es)
|
2015-10-07 |
2018-08-22 |
Hoffmann La Roche |
Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
|
|
EP3365371B1
(en)
|
2015-10-22 |
2025-10-08 |
Ablynx NV |
Gitr agonists
|
|
IL300122A
(en)
|
2015-11-18 |
2023-03-01 |
Merck Sharp ַ& Dohme Llc |
Substances that bind to PD1 and/or LAG3
|
|
ES2954153T3
(es)
*
|
2015-12-22 |
2023-11-20 |
Regeneron Pharma |
Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
|
|
JP7328761B2
(ja)
|
2016-01-11 |
2023-08-17 |
インヒブルクス インコーポレイテッド |
多価多重特異性ｏｘ４０結合融合タンパク質
|
|
IL304871A
(en)
|
2016-01-11 |
2023-10-01 |
Inhibrx Inc |
Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
|
|
GB201602156D0
(en)
|
2016-02-05 |
2016-03-23 |
Jones Philip C And Boku University Of Natural Resources And Life Sciences |
Heterodimers and purification thereof
|
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
|
US20190112380A1
(en)
|
2016-03-29 |
2019-04-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
ES3056995T3
(en)
|
2016-04-13 |
2026-02-25 |
Vivia Biotech Sl |
Ex vivo bite-activated t cells
|
|
BR112018071612A2
(pt)
|
2016-04-22 |
2019-02-19 |
Alligator Bioscience Ab |
polipeptídeos biespecíficos inovadores contra cd137
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
WO2018027025A1
(en)
|
2016-08-03 |
2018-02-08 |
Oncomed Pharmaceuticals, Inc. |
Cd40-binding agents and uses thereof
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
WO2018090950A1
(zh)
*
|
2016-11-18 |
2018-05-24 |
北京韩美药品有限公司 |
抗pd‐1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
CN108084265B
(zh)
|
2016-11-23 |
2021-07-02 |
复旦大学 |
特异性结合人的5t4抗原的全人源单域抗体及其应用
|
|
CA3047070A1
(en)
|
2017-01-03 |
2018-07-12 |
F.Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
|
|
EP3595705A1
(en)
|
2017-03-15 |
2020-01-22 |
Oxford BioMedica (UK) Limited |
Method
|
|
CN110402255B
(zh)
*
|
2017-04-04 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
|
|
MY200973A
(en)
|
2017-04-11 |
2024-01-26 |
Inhibrx Inc |
Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
|
|
EP3502140A1
(en)
*
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
TW202010757A
(zh)
|
2018-04-11 |
2020-03-16 |
美商英伊布里克斯公司 |
具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
|
|
WO2019201866A1
(en)
|
2018-04-16 |
2019-10-24 |
Swedish Orphan Biovitrum Ab (Publ) |
Fusion protein
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
|
|
CN113166261A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
B7h3单域抗体及其治疗性组合物
|
|
AU2019356573B2
(en)
|
2018-10-11 |
2025-12-18 |
Inhibrx Biosciences, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
|
US12590169B2
(en)
*
|
2018-10-11 |
2026-03-31 |
Inhibrx Biosciences, Inc. |
5T4 single domain antibodies and therapeutic compositions thereof
|
|
EP4097129A1
(en)
|
2020-01-29 |
2022-12-07 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|